Objective: To prospectively identify and reduce proximal causes of error contributing to inappropriate intravenous potassium chloride orders and reduce adverse events subsequent to these ordering errors.

Design: Pre-post cohort study of the reduction in both proximal causes of error and number of postinfusion elevated serum potassium levels after intervention.

Setting: Sixteen-bed, tertiary care, urban, academic pediatric intensive care unit.

Patients: Children 0-18 yrs old receiving intravenous potassium chloride in the pediatric intensive care unit.

Interventions: A multidisciplinary team determined proximal causes of error that were likely contributors to the occurrence of the outcome measure, elevated potassium levels after intravenous potassium chloride. A mandatory drug request form was designed for physicians ordering intravenous potassium chloride. The drug request form was designed to reduce proximal causes of error and, as a result, elevated potassium levels after intravenous potassium chloride. Demographic and laboratory data on children receiving intravenous potassium chloride in the pediatric intensive care unit and details of the drug order were analyzed.

Measurements And Main Results: Data from 1,492 intravenous potassium chloride administration-events before implementation of the drug request form were collected. After the drug request form was mandated, 166 consecutively completed forms were collected and analyzed. The incidence of postinfusion elevations in serum potassium decreased from a rate of 7.7% (103 of 1,341) before the drug request form to 0% (0 of 150) after the drug request form (p < .001). Proximal causes of error were also reduced. The number of patients with a creatinine >/=2 mg/dL receiving intravenous potassium chloride decreased from 28.4% to 14.2% (p < .001). The number of intravenous potassium chloride infusions administered to patients where serum potassium value was >4.5 mmol/L decreased significantly (2.9% vs. 0.0%, p < .02). The incidence rates of both verbal orders and failure to write the order in a correct format were reduced to zero.

Conclusions: Simple, blame-free, system-wide interventions designed to reduce proximal causes of error can be an effective, proactive means of reducing the likelihood of medical morbidity.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.PCC.0000149832.76329.90DOI Listing

Publication Analysis

Top Keywords

intravenous potassium
40
potassium chloride
40
proximal error
24
drug request
24
request form
24
pediatric intensive
16
intensive care
16
potassium
15
reduce proximal
12
serum potassium
12

Similar Publications

Objectives: Acetate (ACE) and lactate (LAC)-containing balanced resuscitation fluids are commonly used for fluid therapy in cats. These fluids can influence acid-base and electrolyte status. This prospective randomised study compared two balanced crystalloid solutions regarding their effect on acid-base status, electrolytes and LAC concentrations in dehydrated cats after intravenous fluid therapy.

View Article and Find Full Text PDF

Pharmacological Interventions for the Acute Treatment of Hyperkalaemia: A Systematic Review and Meta-analysis.

Resuscitation

January 2025

Department of Anaesthesiology and Intensive Care, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Electronic address:

Background: Hyperkalaemia is a life-threatening electrolyte disturbance and also a potential cause of cardiac arrest. The objective was to assess the effects of acute pharmacological interventions for the treatment of hyperkalaemia in patients with and without cardiac arrest.

Methods: The review was reported according to PRISMA guidelines and registered on PROSPERO (CRD42023440553).

View Article and Find Full Text PDF

Background: Sepsis represents the most prevalent infectious complication and the primary cause of mortality in myeloproliferative neoplasms (MPN). The risk of sepsis and the difficulty of treatment are significantly increased in MPN patients due to the need for immunomodulators and antibiotics.

Case Presentation: On June 9, 2023, a 69-year-old male was admitted to the hospital.

View Article and Find Full Text PDF

Dexmedetomidine suppresses glucose-stimulated insulin secretion in pancreatic β-cells.

FEBS Open Bio

December 2024

Department of Cell Physiology, Institute of Biomedical Science, Kansai Medical University, Hirakata, Osaka, Japan.

Article Synopsis
  • Proper glycemic control is important in critical care settings, as it can impact patient outcomes and is influenced by factors such as insulin secretion and glucose metabolism.
  • Various perioperative drugs, particularly dexmedetomidine (DEX), are shown to suppress glucose-stimulated insulin secretion, but the mechanisms remain unclear.
  • Research using pancreatic cell lines and primary cells indicates that DEX reduces insulin secretion without significantly altering other cellular processes, suggesting that it affects insulin signaling pathways and exocytosis mechanisms.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!